Jasper Therapeutics Stock Current Asset
| JSPR Stock | USD 2.90 0.08 2.68% |
Fundamental analysis of Jasper Therapeutics allows traders to better anticipate movements in Jasper Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
As of 08/07/2025, Non Current Assets Total is likely to grow to about 4.6 M, while Other Current Assets are likely to drop slightly above 2.4 M. Jasper | Current Asset | Build AI portfolio with Jasper Stock |
Jasper Therapeutics Company Current Asset Analysis
Jasper Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Jasper Current Asset Historical Pattern
Today, most investors in Jasper Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Jasper Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Jasper Therapeutics current asset as a starting point in their analysis.
Jasper Therapeutics Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Jasper Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Jasper Therapeutics has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Stocks Directory Now
Stocks DirectoryFind actively traded stocks across global markets |
| All Next | Launch Module |
Jasper Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Jasper Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Jasper Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Jasper Fundamentals
| Return On Equity | -1.01 | ||||
| Return On Asset | -0.56 | ||||
| Current Valuation | (1.44 M) | ||||
| Shares Outstanding | 15.02 M | ||||
| Shares Owned By Insiders | 1.27 % | ||||
| Shares Owned By Institutions | 89.64 % | ||||
| Number Of Shares Shorted | 1.36 M | ||||
| Price To Book | 1.06 X | ||||
| EBITDA | (71.39 M) | ||||
| Net Income | (71.27 M) | ||||
| Cash And Equivalents | 60.81 M | ||||
| Cash Per Share | 1.60 X | ||||
| Total Debt | 1.81 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 9.56 X | ||||
| Book Value Per Share | 2.81 X | ||||
| Cash Flow From Operations | (62.6 M) | ||||
| Short Ratio | 0.93 X | ||||
| Earnings Per Share | (5.27) X | ||||
| Target Price | 20.13 | ||||
| Number Of Employees | 64 | ||||
| Beta | 2.71 | ||||
| Market Capitalization | 44.77 M | ||||
| Total Asset | 79.9 M | ||||
| Retained Earnings | (240.87 M) | ||||
| Working Capital | 60.57 M | ||||
| Net Asset | 79.9 M |
About Jasper Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jasper Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jasper Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jasper Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Jasper Stock Analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.